Nuveen Asset Management LLC Has $2.11 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Nuveen Asset Management LLC lifted its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 42.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,432,404 shares of the biotechnology company’s stock after acquiring an additional 425,484 shares during the period. Nuveen Asset Management LLC owned approximately 0.21% of OPKO Health worth $2,106,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Numerai GP LLC acquired a new position in shares of OPKO Health in the 4th quarter worth approximately $205,000. Millennium Management LLC lifted its position in OPKO Health by 85.3% during the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 2,112,382 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in OPKO Health by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 8,064 shares during the last quarter. Lazard Asset Management LLC increased its position in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after acquiring an additional 1,502,342 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of OPKO Health by 48.3% in the fourth quarter. Deutsche Bank AG now owns 309,867 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 100,868 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Trading Up 1.5%

NASDAQ OPK opened at $1.38 on Tuesday. OPKO Health, Inc. has a 12 month low of $1.19 and a 12 month high of $2.04. The stock has a 50-day simple moving average of $1.41 and a 200 day simple moving average of $1.54. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.09 billion, a PE ratio of -7.26 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same period in the previous year, the firm posted ($0.12) EPS. The business’s quarterly revenue was down 13.7% compared to the same quarter last year. Research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost acquired 125,000 shares of the business’s stock in a transaction dated Thursday, April 10th. The stock was bought at an average price of $1.36 per share, with a total value of $170,000.00. Following the acquisition, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. This represents a 0.06% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders acquired 700,000 shares of company stock worth $1,123,000. 49.69% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on OPK shares. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They set a “neutral” rating for the company. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.